Alkermes PLC (NASDAQ:ALKS) – Analysts at Leerink Swann dropped their Q4 2017 earnings per share estimates for Alkermes PLC in a report released on Tuesday. Leerink Swann analyst P. Matteis now anticipates that the company will post earnings per share of ($0.05) for the quarter, down from their prior estimate of ($0.04). Leerink Swann currently has a “Market Perform” rating and a $61.00 target price on the stock. Leerink Swann also issued estimates for Alkermes PLC’s FY2018 earnings at ($0.40) EPS.

A number of other equities research analysts have also recently commented on ALKS. Cantor Fitzgerald restated a “neutral” rating and set a $51.00 target price on shares of Alkermes PLC in a research report on Thursday, March 16th. Cowen and Company restated a “positive” rating and set a $65.00 target price on shares of Alkermes PLC in a research report on Tuesday, March 21st. Jefferies Group LLC restated a “buy” rating and set a $70.00 target price on shares of Alkermes PLC in a research report on Monday, April 3rd. Morgan Stanley restated an “equal weight” rating and set a $62.00 target price on shares of Alkermes PLC in a research report on Monday, April 24th. Finally, J P Morgan Chase & Co set a $78.00 target price on Alkermes PLC and gave the company a “buy” rating in a research report on Thursday, April 27th. Six research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $63.10.

COPYRIGHT VIOLATION NOTICE: “Q4 2017 EPS Estimates for Alkermes PLC (ALKS) Decreased by Analyst” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/07/16/q4-2017-eps-estimates-for-alkermes-plc-alks-decreased-by-analyst-updated-updated-updated.html.

Alkermes PLC (NASDAQ ALKS) opened at 57.15 on Thursday. The stock’s market capitalization is $8.75 billion. Alkermes PLC has a 12 month low of $39.65 and a 12 month high of $63.40. The stock has a 50 day moving average price of $58.62 and a 200 day moving average price of $57.17.

Alkermes PLC (NASDAQ:ALKS) last announced its quarterly earnings data on Thursday, April 27th. The company reported ($0.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by $0.07. Alkermes PLC had a negative net margin of 25.61% and a negative return on equity of 9.76%. The business had revenue of $191.80 million during the quarter, compared to analysts’ expectations of $195.79 million. During the same quarter in the previous year, the firm earned ($0.16) earnings per share. Alkermes PLC’s revenue was up 22.3% on a year-over-year basis.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Creative Planning raised its position in Alkermes PLC by 16.2% in the first quarter. Creative Planning now owns 18,012 shares of the company’s stock worth $1,054,000 after buying an additional 2,510 shares during the period. Norges Bank acquired a new position in Alkermes PLC during the fourth quarter worth $44,274,000. Capstone Asset Management Co. raised its position in Alkermes PLC by 8.0% in the first quarter. Capstone Asset Management Co. now owns 6,585 shares of the company’s stock worth $385,000 after buying an additional 490 shares during the period. FMR LLC raised its position in Alkermes PLC by 0.4% in the first quarter. FMR LLC now owns 22,882,118 shares of the company’s stock worth $1,338,604,000 after buying an additional 86,546 shares during the period. Finally, KBC Group NV raised its position in Alkermes PLC by 141.8% in the first quarter. KBC Group NV now owns 225,966 shares of the company’s stock worth $13,219,000 after buying an additional 132,525 shares during the period. 97.33% of the stock is currently owned by institutional investors and hedge funds.

In related news, insider Shane Cooke sold 1,900 shares of Alkermes PLC stock in a transaction dated Tuesday, March 21st. The stock was sold at an average price of $60.09, for a total value of $114,171.00. Following the sale, the insider now directly owns 72,048 shares in the company, valued at approximately $4,329,364.32. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Richard F. Pops sold 50,000 shares of Alkermes PLC stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $58.19, for a total value of $2,909,500.00. Following the completion of the sale, the director now owns 680,406 shares in the company, valued at $39,592,825.14. The disclosure for this sale can be found here. Over the last quarter, insiders sold 174,800 shares of company stock worth $10,136,406. 5.34% of the stock is currently owned by insiders.

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Receive News & Stock Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related stocks with our FREE daily email newsletter.